InfuSystems Holdings Inc. (INFU)
INFU trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1337013/000162828026012804/0001628280-26-012804-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INFU on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001337013 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $143.4M |
| Net income | $6.6M |
| Operating income | $11.9M |
| Net margin | 4.6% |
| Operating margin | 8.3% |
| Revenue growth | +6.4% |
| Cash | $3.2M |
| Total assets | $100.6M |
| P/E (computed) | 44.7× |
| P/S (computed) | 2.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $9.1M cash; operating cash flow $6.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 20,033,488 (2026-11-08); 20,336,183 a year earlier; 21,183,526 three years earlier. | Cover page 2026-11-08 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Detroit, Michigan, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $150K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $37.6M | $3.2M | $10.3M | $9.1M | $19.7M | $144.4M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $36.9M | $3.2M | $6.8M | $964K | $20.4M | $143.3M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $33.7M | $1.0M | $970K | $2.1M | $19.6M | $142.4M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $36.2M | $2.0M | $7.1M | $3.2M | $19.6M | $143.4M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $36.5M | $2.3M | $8.5M | $955K | $20.9M | $141.1M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $36.0M | $2.6M | $7.0M | $720K | $26.3M | $139.9M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $34.7M | -$267K | $1.8M | $1.5M | $28.7M | $137.6M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $33.8M | $933K | $7.9M | $527K | $23.9M | $134.9M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B1 | 2010-10-19 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.5% |
| 1 month | +9.1% |
| 3 months | +17.9% |
| Year to date | +64.1% |
| 1 year | +44.9% |
| From 52-week high | -3.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TMCI | Treace Medical Concepts Inc. | $4.42 | -16.13% | $289.8M |
| OFIX | Orthofix Medical Inc. Common Stock (DE) | $6.80 | -5.16% | $277.2M |
| NPCE | Neuropace Inc. | $7.97 | +5.42% | $274.6M |
| SSII | SS Innovations International Inc. | $1.35 | -18.67% | $270.7M |
| PROF | Profound Medical Corp. | $7.34 | -1.08% | $268.8M |
| CLPT | ClearPoint Neuro Inc. | $8.30 | -2.12% | $266.1M |
| OSUR | OraSure Technologies Inc. | $3.60 | -0.55% | $248.6M |
| EMBC | Embecta Corp. | $6.25 | -3.25% | $354.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier